Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy for Liver Cancer
Study Summary
This trial is testing a combination of immunotherapy and chemotherapy to treat patients with unresectable fibrolamellar cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a live or weakened virus vaccine within the past month before starting the study.You have had cancer, except for non-melanoma skin cancer or early stage cancer that has been treated and you have been cancer-free for at least 2 years.You have had a liver transplant in the past.You have a severe wound, ulcer, or bone fracture that has not healed yet.You have had an organ transplant.You are taking strong medications that suppress your immune system, or high doses of steroids. Exceptions may be made if you experience severe side effects or allergic reactions during the trial.You cannot be dependent on total parenteral nutrition.You have a history of autoimmune diseases like rheumatoid arthritis, lupus, or inflammatory bowel disease.You have a medical condition that could make taking the study drug dangerous or difficult to understand any side effects. For example, if you have a condition that causes frequent diarrhea.You have a history of certain conditions that increase the risk of bowel perforation, such as acute diverticulitis, abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, gastrointestinal obstruction, or abdominal cancer spread.You have a type of brain tumor that is not benign, any brain tumors that have spread from other parts of your body, or any neurological conditions that are not well controlled with standard medications. Additionally, you have had a stroke within the past year.
- Group 1: Treatment (fluorouracil, interferon alpha 2b, nivolumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are enrolled in the experiment?
"Affirmative. The clinicaltrials.gov website confirms that this trial is currently in search of participants and it was first published on January 13th 2021, with the latest update having been registered on September 22nd 2022. This study seeks to enrol 15 patients from one location."
Are there any current possibilities to participate in this experiment?
"Per clinicaltrials.gov, the enrolment process for this trial is ongoing, having first been posted on January 13th 2021 and last updated September 22nd 2022."
Could you provide details on past experiments where Fluorouracil was administered?
"This present moment, there are 1,010 different clinical studies underway centered around fluorouracil. Of these trials, 179 of them have reached Phase 3 with 56959 sites offering the trial worldwide; Woolloongabba in Queensland is one such location."
In what medical circumstances is Fluorouracil typically prescribed as a treatment?
"Fluorouracil is the gold standard for treating classical hodgkin's lymphoma, but it can also be effective against metastatic ureter urothelial carcinoma, metastatic hepatocellular carcinoma and malignant melanomas of skin."
Share this study with friends
Copy Link
Messenger